INTRODUCTION
Magnesium ion (Mg 2þ ) is the most abundant divalent cation in eukaryotic cells and is required for many critical physiological processes. The vast majority of the total body's Mg 2þ content is in a bound form either in the intracellular compartment or in the bone. Most intracellular bound Mg 2þ is tightly associated with nucleotides and proteins, and plays vital roles in energy production, DNA replication, gene transcription, and protein synthesis [1] . Less than 5% of the intracellular Mg 2þ exists in the free (ionized) state, for which magnesium transporter 1 (MAGT1) is a critical regulator [2] .
Loss-of-function mutations in the gene encoding MAGT1 cause XMEN disease, a mild form of combined immune deficiency (CID) that has brought to light novel and fascinating functions of free intracellular Mg 2þ in the immune system.
We now know that a transient T-cell receptor (TCR)-mediated Mg 2þ influx into T cells is a signaling step that enhances the efficiency of the activation of these cells [3] . Intracellular Mg 2þ regulation in the immune system participates in the cytolytic control of Epstein-Barr virus (EBV) infection [4 && ]. An important connection between Mg 2þ and EBV control was recognized in patients with XMEN disease, in whom a decrease in intracellular free Mg 2þ was associated with defective expression of the natural killer (NK) stimulatory receptor 'natural-killer group 2, member D' (NKG2D) in NK and cytotoxic CD8 þ T lymphocytes (CTLs). As a result, XMEN patients have high levels of EBV and an increased number of EBV-infected B cells in the blood. XMEN disease is also associated with an increased susceptibility to EBV-driven lymphoproliferative diseases (LPDs). Moreover, recent in-vitro and preliminary in-vivo studies using oral magnesium L-threonate supplementation in XMEN patients showed an increase of NKG2D in endogenous NK and CTL cells, which led to better control of EBV infection [4 && ]. In the recent years, several primary immunodeficiencies (PID) have thus been associated with abnormalities in ion channels and transporters, including those involved in the permeability and transport of Ca 2þ [5] [6] [7] [8] transportation, chronic EBV infection, increased susceptibility to EBV-associated B-cell lymphoma, decreased CD4 count, and impaired T cell and NKG2D-driven cytolytic function caused by lossof-function mutations in MAGT1.
CLINICAL FEATURES
CIDs are a heterogeneous group of genetic abnormalities that impair both humoral and cell-mediated immunity. In contradistinction to severe combined immunodeficiency (SCID), in which, if left untreated, patients usually succumb to severe infections within the first year or two of life, XMEN disease has a more indolent clinical course. EBVassociated B-cell lymphoproliferation ultimately emerges in late childhood to be the most common cause of severe morbidity and mortality in this patient population. The prevalence of XMEN disease is unknown, but it is expected to be uncommon. Only seven male patients with XMEN disease have been reported in the scientific literature and the frequency of female carriers has not yet been defined [9 && ]. More recently, a lower number of unpublished male cases have been identified. As the association between MAGT1 loss-of-function mutations and immune disease was not recognized until 2011, increased awareness of XMEN disease in the medical community might lead to identification of new cases, especially in male patients with a history of persistently elevated EBV viral loads and EBVassociated LPDs.
In our experience at the National Institutes of Health, the age at diagnosis varies from 3 to 45 years [9 && ]. Recurrent sinopulmonary infections and viral pneumonias have been reported in some, but not all, patients with XMEN disease. Interestingly, EBVassociated lymphomas have been the only reason some patients with XMEN disease come to medical attention. As XMEN is an X-linked disease, all patients with clinical disease to date have been men. Women with verified mutations in the gene that encodes MAGT1 have all been unaffected heterozygous carriers with skewed lyonization, favoring the expression of the wildtype X chromosome. As in other X-linked diseases, there is a theoretical possibility of clinical disease because of homozygous MAGT1 mutations in women from an inbred population, an abnormally skewed female carrier toward the mutant X chromosome, or even less likely, the coexistence of a MAGT1 mutation and an X chromosome monosomy (Turner's syndrome) in the same individual.
The major clinical features of XMEN disease include persistent elevation in EBV-viral load, EBV-associated lymphoproliferative disorders, often with splenomegaly, dysgammaglobulinemia, and decreased CD4/CD8 ratio. The most common clinical characteristic among all patients with XMEN has been a persistent elevation in EBV viral load with an associated increased susceptibility to EBV-driven, B-cell lymphomas and lymphoproliferative disorders [3] . The amount of EBV virus in peripheral blood in XMEN disease also varies among individuals, with values ranging from a thousand to millions of copies per milliliter, as determined by the quantitative real-time polymerase chain reaction (PCR EBV-associated B-cell LPD; two individuals have evidence of two independent primary lymphomas. Two patients aged 23 and 45 years died of transplantrelated complications shortly after undergoing hematopoietic stem cell transplantation (HSCT).
Additionally, XMEN patients may have susceptibility to sinopulmonary and ear infections, viral pneumonias, and other viral infections, but these are generally mild or infrequent. Cutaneous viral infections such as molluscum contagiosum (MCV) have only been reported in one XMEN child. However, MCV is not confined to PID patients, and it is estimated that approximately less than 5% of children in the United States show clinical evidence of MCV infection, indicating the XMEN association may be coincidental [14] . Human papilloma virus (HPV) infections are not commonly observed. Severe varicella infection followed by recurrent herpes zoster was reported in one patient. Neither clinically significant fungal infections nor persistent cytomegalovirus (CMV) infection have been observed. Mild elevations in liver transaminases with no other associated gastrointestinal symptoms or abnormalities have been transiently seen in some patients, likely secondary to chronic EBV infection. Autoimmune cytopenias are not a cardinal feature, but autoimmune hemolytic anemia, thrombocytopenia, and neutropenia have been reported in two patients.
Patients with XMEN have normal growth and development, and no evidence of mental retardation has been identified in any of these patients. These findings are consistent with the recent work that found the previous implications of MAGT1 in mental retardation to be unsupported [15 & ]. Failure to thrive -a common feature in SCID -has not been reported in XMEN disease.
XMEN disease shares some similarities with other PIDs, including those characterized by increased susceptibility to EBV infections, an oncogenic B-cell-tropic gammaherpesvirus that is widespread and infects the majority of children and adults worldwide [16] . EBV is the main causative agent of asymptomatic toddler infections and infectious mononucleosis in teenagers, but generally persists as a latent life-long infection in most adults, and has been associated with T, B, and Hodgkin's lymphomas as well as nasopharyngeal carcinoma. The autosomal recessive interleukin-2 inducible tyrosine kinase (ITK) deficiency is also characterized by EBV-associated lymphoproliferation [17] [18] [19] [20] . However, ITK deficiency has a more severe clinical course of immune dysregulation and rapid disease progression compared with XMEN. CD4 lymphopenia can be seen in both XMEN and a subgroup of patients with ITK deficiency [19] , but decreased number of invariant natural killer T (iNKT) cellsa hallmark of ITK deficiency -is not seen in XMEN disease. Absent or low iNKT cells in the setting of persistent EBV infection are also seen in X-linked lymphoproliferative (XLP) disease because of the deficiency of SLAM-associated protein (SAP) or X-linked inhibitor of apoptosis protein (XIAP). The latter was previously considered a form of XLP (XLP2) but has more recently been classified as an X-linked familial hemophagocytic lymphohistiocytosis (HLH) [21, 22] . Fulminant infectious mononucleosis (FIM), the most common clinical manifestation of XLP, has not been observed in XMEN disease. HLH, a common EBV-triggered complication in XIAP, rarely occurs in XMEN. We have only observed EBV-positive LPDs in XMEN. Persistent symptomatic EBV viremia is seen in CD27 deficiency, a form of combined immunodeficiency associated with hypogammaglobulinemia and impairment in specific-antibody function, resulting from disturbed CD8
þ T cell and T-cell-dependent B-cell responses [23] . However, the level of EBV viremia in the two cases with CD27 deficiency reported to date has been lower (range <50-234 copies/ml) than what is usually seen in XMEN. Chronic EBV viremia with or without associated persistent CMV viremia has been described in individuals with a p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) disease, also known as activated PI3K-delta syndrome (APDS) [24
. In contrast to XMEN, a major hallmark of PASLI is the presence of lymphoid nodules on the respiratory and gastrointestinal tracts and a shift of naïve to senescent T cells. Other primary immunodeficiencies characterized by increased susceptibility to EBV-associated lymphoproliferation include coronin-1A deficiency [26] and MST1 deficiency [27, 28] .
GENETICS
XMEN disease is caused by the loss-of-function mutations in MAGT1. In humans, the MAGT1 gene is located on chromosome Xq21.1. MAGT1 is a 10-exon gene that may have multiple in-frame translation initiation sites. It encodes the transmembrane protein MAGT1, an evolutionary conserved, magnesium-specific transporter protein with little similarity to any known transporter except the tumor suppressor candidate 3 (TUSC3), a nonselective Mg 2þ transporter and candidate tumor-suppressor gene originally named N33 and located on the chromosomal band 8p22 [29, 30] . The human MAGT1 has a 66% amino acid sequence homology with the human TUSC3 and both genes have similar predicted secondary structures. The full-length MAGT1 protein has 367 amino acids, a large amino-terminal segment, 4 transmembrane domains, and a small carboxy-terminal tail [29, 30] . Mutations in TUSC3 have been associated with nonsyndromic autosomal recessive retardation [31] [32] [33] [34] , prostate cancer [35] , and ovarian cancer [36, 37] , which have not been observed in XMEN disease.
Several different MAGT1 mutations have been identified in patients with XMEN. In all cases, the resulting changes in the DNA sequence have led to premature translational termination with nonsensemediated decay of the mRNA [3] . In our experience, the time to onset of lymphoma in XMEN cannot be predicted by the MAGT1 genotype alone. Whether the age of first exposure to EBV or other environmental factors plays a role in the clinical presentation remains to be determined.
Normal women transcriptionally silence one of their two X chromosomes in each somatic cell, by a process called X-chromosome inactivation (XCI) or lyonization. The pattern of XCI in somatic progenitor cells is transmitted to its progeny in a highly stable manner. In some PIDs, such as X-linked chronic granulomatous disease (CGD), the normal and abnormal population of phagocytes coexists in the female carriers. Thus, one cell population will express the wildtype CYBB, the causative gene of X-linked CGD, and have normal superoxide production, whereas the other population will carry the affected allele, yielding the characteristic mosaic pattern with oxidative testing [38] . In other X-linked PIDs, the abnormal allele interferes with the normal cell development, and the affected cell line in female carriers will be predominantly comprised of cells bearing the wildtype gene. As an example, female carriers with mutations in the Bruton tyrosine kinase (BTK) gene that causes X-linked agammaglobulinemia (XLA) have only one population of B cells, deriving from precursor B cells that express the normal BTK allele because of skewing of survival of B cells having inactivated the X chromosome harboring the defective BTK allele [39, 40] . As a result of the small number of XMEN cases reported to date, only a few female carriers have undergone XCI analysis. Notably, the mother and grandmother of two XMEN patients have completely skewed XCI, favoring the expression of the wildtype X chromosome only in the hematopoietic lineages and not in the epithelial cells [3] . This suggests the possibility of a selective developmental disadvantage in hematopoietic cells or their progenitors expressing only the mutant MAGT1 allele.
PATHOGENESIS
MAGT1 is ubiquitously expressed in all mammalian cells. It is a highly selective Mg 2þ transporter with little permeability to other divalent cations [41] . MAGT1 is a cell-surface (plasma membrane) protein that governs the balance of Mg 2þ between the extracellular fluid and the intracellular free basal pool [29] influx, which appears to be a MAGT1-independent process [3] .
Another consequence of a loss of function in MAGT1 is a chronic decrease in the basal level of intracellular free magnesium, leading to reduced expression of the activator receptor NKG2D on NK cells and CD8 þ T cells [3,4 && ,9 && ] (Fig. 1) . NKG2D has important functions in the cytolytic control of EBV-infected cells and tumor surveillance. XMEN is the first PID associated with decreased expression of NKG2D. Impaired NGK2D function may account for the persistent EBV viremia and increased susceptibility to EBV-driven LPDs seen in XMEN, even though these patients are capable of generating EBV-specific cytotoxic T lymphocytes in vivo [4 && ]. Importantly, in-vitro studies of XMEN patients' cells show that supplementation of the tissue culture medium with magnesium sulfate (MgSO 4 ) leads to a partial but significant recovery of NKG2D expression and better cytotoxic function in both NK and CD8 þ T cells [4 && ]. This has also been observed in vivo in XMEN patients receiving oral supplementation with high-dose magnesium L-threonate [4 && ]. Finally, MAGT1 is homologous to a subunit of yeast oligosaccharyl transferase (OST) and its precise cellular functions have not been fully determined. A recent study suggests that MAGT1 can also serve as an endoplasmic reticulum (ER)-localized subunit of the OST complex involved in N-glycosylation of specific glycoproteins [43 && ]. Further investigation is required to determine the MAGT1 role in glycosylation in healthy and diseased lymphocytes.
DIAGNOSIS AND TREATMENT
XMEN disease should be suspected in male individuals with unexplained chronic, especially highlevel, elevations in EBV viremia, splenomegaly, and a personal or family history of EBV-positive B-cell LPDs. EBV serologies may show evidence of past infection. EBV DNA PCR is used to determine and follow-up EBV viremia in XMEN. Measurements for this assay vary widely from center to center, but this should be improved with the implementation of the WHO international standards in the near future. Quantification of EBV-infected B cells by flow cytometric fluorescence in-situ hybridization (FISH) is a novel technique used in some research laboratories and will show elevated values in XMEN patients. XMEN patients may present with an inverted CD4 : CD8 ratio and a reduced number of CD31 þ cells in their naïve CD4 þ T-cell population, suggesting decreased thymic output [3, 9 && ]. Additionally, XMEN is associated with B-cell lymphocytosis because of chronic EBV infection [ with XMEN disease [9 && ]. When available, testing for a decreased NKG2D expression in CD8 þ T cells and NK cells, as detected by flow cytometry on wholeblood samples, strongly supports the diagnosis of XMEN disease. Downregulation of NKG2D has also been described in the setting of malignancies [44] , and confirmatory genetic testing for MAGT1 should be pursued. In the United States, MAGT1 exon sequencing can be currently performed through the Cincinnati Children's Molecular Genetics Laboratory or through the National Institutes of Health Clinical Center. is not yet known whether this is sufficient to prevent EBV-driven lymphoproliferative complications. Ablative B-cell therapy with the anti-CD20 antibody rituximab has been successfully used in a few XLP patients to control acute EBV infection and prevent FIM [45] .
However, rituximab does not completely deplete CD20 þ B cells in tissues [46] and does not prevent the development of EBV-positive CD20
À lymphoproliferative lesions [47] . Autologous virus-specific T-cell therapy may also be used, but it is unlikely to completely overcome the impaired EBV-specific killing defect seen in T cells in XMEN disease [4 && ]. Matched third-party EBV-specific T cells may be a therapeutic option in XMEN. Although the only two XMEN patients who underwent HSCT for the treatment of EBV-positive tumors died of transplantrelated complications, HSCT may still be potentially curative and could be considered for patients with biopsy-proven lymphoproliferative malignancies or for those who are in remission after successful chemotherapy [9 && ]. Given the small number of XMEN cases reported to date, the natural history of the disease is not well known, which complicates making firm therapeutic considerations regarding HSCT, especially in patients who have no clinical or laboratory evidence of an ongoing lymphoproliferative process.
CONCLUSION
XMEN disease has revealed a novel role for free intracellular magnesium regulation in the immune system. XMEN patients do not suffer from overwhelming infections as seen in SCID or other CIDs, which is consistent with the mild T-cell activation defect in these individuals. XMEN has been defined only recently and the long-term natural history of disease is currently uncertain. Thus far, the morbidity associated with XMEN disease appears to result mainly from failure of the immune system to control EBV infection, which invariably leads to EBV-driven malignancies. Given the role for NKG2D in tumor surveillance, it is unknown whether acquisition of EBV infection is necessary for the development of malignancies in XMEN. Mg 2þ supplementation safely increases the basal intracellular Mg 2þ pool in XMEN lymphocytes and NK cells, increasing NKG2D expression and ultimately decreasing EBV viremia. Thus, this therapeutic approach may prove beneficial in the long term for XMEN. Increased awareness of this disease in the medical community may help identify new XMEN cases and increase our understanding of the natural history of this disease. Further clinical trials will be necessary to explore the therapeutic options in XMEN.
